Humaliv 5000mg Injection contains L-Ornithine L-Aspartate 5000mg as its active ingredient, a well-established hepatoprotective agent used primarily in the management of hepatic encephalopathy and other liver-related disorders. This injectable formulation facilitates the detoxification of ammonia by enhancing the urea cycle and promoting the conversion of ammonia into urea and glutamine, thereby reducing elevated blood ammonia levels commonly observed in patients with liver dysfunction. Humaliv 5000mg is indicated for the treatment of acute and chronic hepatic encephalopathy, hyperammonemia, and as an adjunct therapy in cirrhosis and other hepatic insufficiencies. The administration of this injection is typically performed intravenously or intramuscularly under medical supervision, ensuring rapid onset of action and improved bioavailability compared to oral formulations. Clinical studies have demonstrated its efficacy in improving neurological symptoms associated with hepatic encephalopathy, including confusion, altered consciousness, and cognitive impairment. Humaliv 5000mg Injection is generally well-tolerated; however, it should be used with caution in patients with hypersensitivity to any component of the formulation. Dosage and duration of therapy must be individualized based on the severity of the condition and patient response, with close monitoring of liver function and ammonia levels recommended throughout the treatment course.